Scientists Found a New Reason Muscles Lose Strength With Age

Key takeaways

• Age-related strength loss may reflect more than shrinking muscle: the final handoff between nerve and muscle becomes less reliable, making muscle fibers less responsive to the signal to contract.

• The researchers linked that failure point to lower levels of NaV1.4, a channel that helps muscle fibers generate the electrical response needed for contraction.

• In an animal model, partially inhibiting a separate channel, ClC-1, increased muscle responsiveness to nerve signals and improved strength.

• The study includes evidence from human tissue and animal models, but the reversal experiment was performed in animals. This is a potential drug target, not a strength-preserving treatment available today.

Strength is usually discussed as a muscle-size problem. With age, people tend to lose muscle mass, and the standard countermeasure follows logically: preserve or build tissue through resistance training, adequate protein, and enough overall movement.

That model is incomplete. Muscle only produces force after receiving and responding to a signal from a motor nerve. The connection point is the neuromuscular junction—an extraordinarily fast relay that tells a muscle fiber when to contract.

This study suggests that the relay itself becomes less dependable with age. In other words, a muscle may still be present but less able to respond fully when the nervous system calls on it.

A missed failure point

The researchers focused on the last step of the nerve-to-muscle message: the moment when the muscle fiber must translate the incoming signal into its own electrical activation.

They found reduced levels of NaV1.4 in aging muscle. NaV1.4 is a sodium channel, a protein embedded in the muscle-cell membrane that helps create the electrical impulse that initiates contraction. When there is less of it, the threshold for activating the muscle may be harder to reach.

The conceptual shift is important. Some loss of physical capacity may stem not only from having less muscle or fewer nerve inputs, but from a communication bottleneck between the two.

Making fibers easier to activate

The team then tested whether they could compensate for this bottleneck by partially inhibiting ClC-1, a chloride channel in muscle fibers.

Chloride channels help control muscle excitability. Partially reducing ClC-1 activity makes it easier for a muscle fiber to respond to a nerve signal. Rather than adding muscle tissue or replacing nerve cells, the approach aims to improve the performance of the muscle that remains.

In the animal model, this intervention improved responsiveness to nerve signals and increased strength. The finding is compelling because it identifies a potentially modifiable part of the system—not simply a consequence of aging to accept as fixed.

A longevity lens

The study supports a broader view of functional aging: capacity depends on coordination across systems, not just the condition of a single tissue. Muscle mass matters, but so do neural drive, neuromuscular transmission, mitochondrial function, tendon stiffness, balance, and the ability to recruit muscle fibers effectively.

This does not change the basics. Strength training remains the most established way to maintain muscle and function, while adequate protein, regular physical activity, and sleep support adaptation and recovery. But it does help explain why muscle size and strength do not always move in lockstep.

The takeaway

This is a strong mechanistic finding, not an invitation to seek a channel-modulating drug. The study identifies age-related weakness as, in part, a communication problem—and shows in animals that the system can be made more responsive.

The longer-term possibility is a new category of intervention: not building bigger muscles, but helping existing muscle fibers hear the nervous system’s message more clearly.

Reference:
Arnold WD, Morgen JJ, Thomasen PB, et al. Neuromuscular junction failure in sarcopenia is linked to NaV1.4 loss and reversed by ClC-1 inhibition. Journal of Clinical Investigation. 2026;136(17). doi:10.1172/JCI190646.